Drs. Lengyel, Romero, and Fleming are co-leaders of a project chosen by the Mayo Clinic Specialized Program of Research Excellence (SPORE)

Synopsis: Administration of metformin, an oral biguanide prescribed for diabetic patients to improve glycemic control, was shown in independent retrospective analyses by investigators at the University of Chicago and Mayo Clinic to be associated with improved progression-free survival of diabetic ovarian cancer patients compared to diabetic ovarian cancer patients treated with other agents.

Click here to read more about:  PROJECT 3: Metformin as a Metabolic Therapeutic in Ovarian Cancer 

The Department of Obstetrics and Gynecology